FTC Told Impax Can't Justify Opana Reverse Payment
Federal Trade Commission attorneys looking to revive a pay-for-delay case over the opioid pain medication Opana ER told the commission that the central issue in the appeal is that generics maker...To view the full article, register now.
Already a subscriber? Click here to view full article